Introduction {#s1}
============

Unlike damaged peripheral nerves, the central nervous system does not successfully regenerate after injury. Failure to regenerate has been attributed to two components of the regeneration response: intrinsic and extrinsic factors. While extrinsic inhibitory factors such as the glial microenvironment can be modulated with some success, regeneration potential is still substantially hindered, providing evidence that intrinsic factors play a significant role in modulating the ability of an axon to regenerate ([@bib21]; [@bib18]; [@bib13]; [@bib9]; [@bib20]; [@bib37]; [@bib19]; [@bib25]; [@bib30]). Developing an understanding of the intrinsic mechanisms that regulate regeneration will provide insight into the treatment of neurological injury and disease.

DLK-1 (Dual Leucine Zipper Kinase) is a mitogen activated protein kinase kinase kinase (MAPKKK) identified in *C. elegans* that functions intrinsically to regulate regeneration of adult axons in the central and peripheral nervous systems across species, including flies and mammals ([@bib14]; [@bib35]; [@bib33]; [@bib24]; [@bib31]; [@bib32]; [@bib7]). Activation of *dlk-1* enhances axon regeneration and loss of *dlk-1* function inhibits axon regeneration in young and aged animals ([@bib14]; [@bib35]; [@bib7]). In worms, flies, and mice, the function of DLK signaling in regeneration depends on gene transcription ([@bib33]; [@bib24]; [@bib34]; [@bib32]; [@bib29]). These data suggest that specific targets of DLK transcriptional regulation may mediate the ability of DLK signaling to promote regeneration. Further, these targets may identify novel aspects of the cell biology of axon regeneration. Finally, modulation of these targets might increase the intrinsic regenerative potential of injured axons.

Results and discussion {#s2}
======================

To identify targets of DLK transcriptional regulation in neurons, we took advantage of a recently developed method that uses FACS to isolate *C. elegans* neurons and compare their gene expression profiles ([@bib27]). We sorted GABA motor neurons from animals with activated DLK signaling (*dlk-1(OE)*, conferred by overexpression of DLK-1L \[[@bib14]; [@bib34]\]) and compared them to *wild-type* GABA neurons. To control for potential off-target effects of DLK activation, we also analyzed neurons that contained both *dlk-1(OE)* and a loss of function mutation in *pmk-3,* the MAP kinase at the end of the canonical DLK signaling pathway ([@bib17]; [@bib14]; [@bib34]). RNA sequencing and analysis suggested the *parg* genes as candidates for further evaluation. The gene *parg-2* (poly(ADP-ribose) glycohydrolase-2) was significantly upregulated in neurons with activated DLK signaling (187-fold upregulated in *dlk-1(OE)* vs *wild type*, p\<0.01, two-way ANOVA, Bonferroni post-test) ([Figure 1A](#fig1){ref-type="fig"}). Further, examination of RNA-Seq results for the *parg-*2 paralog, *parg-1,* detected a 2.5-fold increase in the *dlk-1(OE)* background compared to *wild type* (p\<0.05, two-way ANOVA, Bonferroni post-test, [Figure 1A](#fig1){ref-type="fig"}) (See Materials and methods). Elevated expression of *parg-1* and *parg-2* by DLK signaling depended on the canonical DLK MAP kinase pathway since up-regulation was eliminated in neurons that over-expressed *dlk-1* but lacked its downstream effector *pmk-3* ([Figure 1A](#fig1){ref-type="fig"}). These data suggested that regulation of PARG function might be a major effect of DLK signaling. Overall, up-regulation (\>two fold, p\<0.05) (See Materials and methods) of gene expression by DLK signaling was observed for only 1.9% of coding genes (386 out of 20,375 protein coding genes assayed); expression of most genes was not affected by DLK signaling. For example, expression levels of the pan-neuronal control gene *rgef-1* (a ras nucleotide exchange factor) were not altered in either mutant background ([Figure 1A](#fig1){ref-type="fig"}). Together, our data indicate *parg* expression is regulated by DLK signaling in GABA neurons.10.7554/eLife.12734.003Figure 1.PARG genes regulate axon regeneration.(**A**) *dlk-1* overexpression upregulates *parg-1* and *parg-2* expression levels in GABA neurons. The upregulation is suppressed by loss of *pmk-3* function. *rgef-1* (a pan-neuronal Ras nucleotide exchange factor) expression levels are not affected by manipulations of the *dlk-1* pathway (\*p\<0.05, \*\*\*p\<0.01, two-way ANOVA, Bonferroni post-test). (**B**--**C**) *dlk-1* regulates expression of nuclear-localized mCherry driven by the *parg-2* promoter. *Pparg-2::NLS::mCherry::NLS* was observed (arrows) in 90% of nuclei of GABA neurons in *dlk-1(OE)* animals and in 19% of GABA neurons in *wild type* animals (asterisks). GABA neurons express GABA neuron-specific GFP marker, *Punc-47::GFP*. (**C**) *parg-2* expression was significantly increased in both severed axons and neighboring uncut axons relative to axons in uninjured *wild type* animals. *parg-2* was not expressed in *dlk-1(lf)* axons, whether severed or intact. (\*p\<0.05, Fisher's exact test, relative to wild type, n = 111, 20, 115, 34, 18, 69, 36). (**D**) The GABA motor nervous system of *C. elegans*. GFP-labeled axons were severed with a pulsed laser at the midline (dark brown line) and scored for regeneration. (**E**) Representative micrographs of uninjured *wild type*, severed *wild type*, severed *parg-1(-)*, and severed *parg-2(-)* GABA axons. Each carry the *oxIs12* transgene which drives GFP expression in GABA neurons. Arrowheads and arrows indicate proximal and distal stumps, respectively. (**F**) Axon regeneration is significantly reduced in *parg-1(-), parg-2(-)* and *parg-1(-) parg-2(-)* mutants compared to wild type animals (\*p\<0.05, Fisher's exact test, relative to wild type, n = 50, 39, 67, 21). (**G**) *parg-1* and *parg-2* are closely linked on chromosome IV, making construction of a double mutant difficult. To create a double *parg-1 parg-2* mutant, *parg-1* was mutated with CRISPR in a *parg-2(lf)* background. The resulting frameshift mutation (*wp20*) truncates PARP-1 earlier than the canonical *gk120* deletion allele. (**H**) Expression of *parg-1* or *parg-2* in GABA motor neurons rescued axon regeneration in *parg-1(lf)* and *parg-2(lf)* mutants, respectively. (**I**) Model of PARG function in axon regeneration.**DOI:** [http://dx.doi.org/10.7554/eLife.12734.003](10.7554/eLife.12734.003)

To further test whether DLK regulates *parg* expression in GABA neurons, we built a reporter construct that expresses nuclear-localized mCherry driven by the *parg-2* promoter. At low magnification (4X), mCherry was only detected in *dlk-1(OE)* animals (20/20 *dlk-1OE* animals, 0/20 wild type animals). At high magnification (40X), mCherry was seen in 90% of GABA neurons in *dlk-1(OE)* animals and 19% of GABA neurons in control animals ([Figure 1B,C](#fig1){ref-type="fig"}) (p\<0.0001, Fisher's exact test). mCherry was not detected in *dlk-1(lf)* animals, which lack DLK-1. Therefore, *parg-2* expression is dependent on *dlk-1*, even in intact, uninjured axons.

Next, we tested the effect of axon injury on *dlk-1-*dependent *parg* expression ([Figure 1B,C](#fig1){ref-type="fig"}). Approximately 10 hr post-axotomy, *parg-2* expression was significantly elevated in cut GABA axons relative to *parg-2* expression in GABA axons of uninjured animals (47% vs 19%, p=0.0028, Fisher's exact test). Further, by examining neighboring uncut GABA axons, we found that *parg-2* expression also increased in uninjured neurons to equivalent levels (47% vs 41%, p=0.6722, Fisher's exact test). The increase in *parg-2* expression in response to injury is entirely dependent on *dlk-1*, as *parg-2* expression was not seen in cut or uncut axons in injured *dlk-1(lf)* animals (p=0.0003 and p=0.0001, relative to cut axons and uncut axons in injured wild type animals). Thus, *parg-2* expression is upregulated in injured neurons and their neighbors, and dependent on *dlk-1.*

Poly(ADP-ribose) glycohydrolases (PARGs) catalyze dePARylation: the removal of the post-translational modification poly(ADP-ribose) (PAR) from target proteins ([@bib16]; [@bib1]). The *parg-1* and *parg-*2 genes encode the only two PARGs in the *C. elegans* genome ([@bib11]). We determined the function of *parg-1* and *parg-*2 in axon regeneration by assessing regrowth after single neuron laser axotomy in GABA neurons ([@bib6]) ([Figure 1D](#fig1){ref-type="fig"}). Loss of either *parg-1* or *parg-2* reduced axon regeneration to approximately half of normal levels: only 39% and 36% of axons regenerated in *parg-1* and *parg-2* mutants, respectively, while 70% of axons regenerated in control animals ([Figure 1E,F](#fig1){ref-type="fig"}). Therefore, *parg-1* and *parg-2* regulate axon regeneration.

The *parg-1* and *parg-2* genes are closely linked on chromosome IV, complicating generation of a double mutant. To assess whether complete elimination of PARG activity could further reduce regeneration, we used a CRISPR-Cas9 approach ([@bib10]) to mutate *parg-1* in the *parg-2(lf)* background ([Figure 1G](#fig1){ref-type="fig"}). The resulting *parg-1(lf); parg-2(lf)* double mutant was viable and displayed wild-type morphology and behavior, indicating PARG function is not essential. Axon regeneration in *parg-1(lf); parg-2(lf)* animals was similar to axon regeneration in either *parg-1* or *parg-2* mutant animals ([Figure 1F](#fig1){ref-type="fig"}). Thus, PARG activity is required for normal axon regeneration, but some regeneration occurs even in animals that completely lack *parg.*

To test whether the *parg* genes act within GABA neurons to regulate axon regeneration, we reintroduced *parg-1* or *parg-2* specifically in GABA neurons (using the *unc-47* promoter) of *parg-1(lf)* or *parg-2(lf)* mutants, respectively, and assessed regeneration. We found that 87% and 85% of injured axons regenerated in *parg-1* and *parg-2* worms whose GABA neurons had restored PARG expression ([Figure 1H](#fig1){ref-type="fig"}). We conclude cell-intrinsic PARG function is required for axon regeneration of GABA neurons ([Figure 1I](#fig1){ref-type="fig"}).

Cellular levels of PARylation are determined by the balance between the activity of PARGs, which remove PAR, and the activity of poly (ADP-ribose) polymerases (PARPs), which transfer PAR onto target proteins ([@bib23]; [@bib12]). Thus, axon regeneration defects in *parg-1* and *parg-2* mutants ([Figure 1F](#fig1){ref-type="fig"}) could be due to accumulation of PAR. To test this hypothesis, we analyzed regeneration in animals with reduced PAR. The *C. elegans* genome contains two PARP homologs, *parp-1 and parp-2* ([@bib11]). We found that mutation of either *parp-1* or *parp-2* increased axon regeneration relative to control animals: 92% and 90% of axons regenerated in *parp-1* and *parp-2* mutants, respectively, while 76% of axons in controls regenerated ([Figure 2A,B](#fig2){ref-type="fig"}). Regenerating axons in these assays include all those that initiate a migrating growth cone after injury. To determine whether axons in PARP mutants are capable of sustained growth toward their original target, we assessed ability to extend towards the dorsal nerve cord ([Figure 2C](#fig2){ref-type="fig"}). We found that 56% and 53% of regenerating axons in *parp-1* and *parp-2* mutants, respectively, regrew at least 3/4 of the distance between the ventral and the dorsal nerve cords compared to only 26% of regenerating axons in controls ([Figure 2D](#fig2){ref-type="fig"}). Moreover, some *parp-2* mutants sprouted new axons from the cell body ([Figure 2E](#fig2){ref-type="fig"}). The opposing effects of PARGs and PARPs on poly(ADP)-ribose and on axon regeneration indicate that PARylation is a critical determinant of regenerative potential.10.7554/eLife.12734.004Figure 2.PARPs inhibit axon regeneration.(**A**) Representative micrographs of severed wild type, *parp-1(lf)*, and *parp-2(lf)* GABA motor neurons. (**B**) Axon regeneration in *parp-1(lf)* and *parp-2(lf)* mutants compared to wild type animals (\*p\<0.05, Fisher's exact test, n = 84, 26, 61). (**C**) Cut axons (1) are scored for the distance they extend towards their targets in the dorsal nerve cord (2, 3, 4, 5). (**D**) Axon regeneration to at least 3/4 of the distance to the dorsal cord (4) is significantly increased in *parp-1(lf)* and *parp-2(lf)* mutants relative to *wild type* animals (\*p\<0.01, Fisher's exact test, n = 61, 43, 38). (**E**) Axon regeneration from the cell body (2) is seen in *parp-2(lf)* mutants (n = 47, 32, 34). (**F**) Representative micrographs of injured cortical neurons exposed to negative control shRNA or PARP1 shRNA. (**G**) Axon regeneration is increased in murine cortical neurons lacking PARP1 (\*\*\*p\<0.001, \*\*\*\*p\<0.0001, Anova with Tukey's multiple comparisons test, n = 108, 8, 8). Axon regeneration was measured in injured cortical neurons exposed to non-coding negative control shRNA (shNC) or either of two unique PARP1 shRNAs. (**H**, **I**) Exposure to either shPARP significantly reduced PARP levels in cortical neurons relative to PARP levels in cortical neurons exposed to negative control (shNC) lentivirus (\*p\<0.05, \*\*p\<0.005, Anova with Tukey's multiple comparisons test). (**J**) *parg-1* and *parg-2* loss of function incompletely suppress the increase in regeneration conferred by *dlk-1*(*OE*) (\*p\<0.05, relative to *wild type*, §p\<0.05, relative to *dlk-1*(*OE*), Fisher's exact test, n = 24, 21, 48, 62), indicating the PARGs regulate regeneration downstream of *dlk-1* with at least one parallel pathway.**DOI:** [http://dx.doi.org/10.7554/eLife.12734.004](10.7554/eLife.12734.004)10.7554/eLife.12734.005Figure 2---figure supplement 1.Detailed characterization of regeneration in *dlk-1(OE)* and *parg-2(-) parg-2(-)* mutants.For each severed axon represented in [Figure 2H](#fig2){ref-type="fig"}, we determined whether a given axon regenerated below the midline of the worm (M-), beyond the midline (M+), at least 3/4 of the distance to the dorsal cord (M++). The greatest difference in regenerative ability between the genotypes is in overall regeneration, represented by combining the blue bars for each genotype.**DOI:** [http://dx.doi.org/10.7554/eLife.12734.005](10.7554/eLife.12734.005)

PARG and PARP function are well-conserved between *C.elegans* and mammals ([@bib11]; [@bib28]). Therefore, we hypothesized that blocking PARP function might be sufficient to improve regeneration of mammalian CNS neurons. To test this hypothesis, we assessed the effect of PARP knockdown on mouse cortical neuron regeneration. We cultured primary cortical mouse neurons in 96-well plates ([@bib15]). We subsequently added lentiviral control or one of two unique PARP1 shRNAs at three days in vitro (DIV), and injured the neurons with a custom pin-replicator five days later ([@bib15]). Three days after injury, we fixed the neurons and assessed regeneration. We found that axons exposed to PARP1 shRNA regenerated significantly better than axons exposed to control shRNA ([Figure 2F,G](#fig2){ref-type="fig"}). To confirm the shRNA clones targeted PARP1, we performed western blots on cortical neurons exposed to the negative control shRNA or to the two unique shRNA that target PARP1. In each case PARP was detected in the insoluble fraction and not in the lysate, in agreement with previously reported localization to the nucleus (reviewed in [@bib3]). PARP was significantly reduced in neurons exposed to either of the PARP1-targeting shRNAs compared to negative control shRNA ([Figure 2H,I](#fig2){ref-type="fig"}). PARP levels were normalized to actin levels in each sample of neurons. Therefore, PARP-1 and PARylation are conserved inhibitors of axon regeneration after injury, and reducing their function improves axon regeneration across species.

Having established that PARGs are novel regulators of axon regeneration, we sought to determine the extent to which DLK function is mediated by PARGs. We assessed regeneration in animals with activated DLK signaling (*dlk-1(OE)*), but lacking both *parg-1* and *parg-2.* We found that loss of both *parg-1* and *parg-2* function reduced regeneration in the *dlk-1(OE)* background, just as loss of *parg-1* and *parg-2* reduces regeneration in animals with wild type levels of DLK signaling ([Figure 2J](#fig2){ref-type="fig"} and [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). In both cases, regeneration is reduced but not eliminated, and the amount of regeneration that remains is higher than complete loss of *dlk-1* signaling (0% regeneration) or loss of the downstream *pmk-3* in the *dlk-1(OE)* background (7% regeneration) ([@bib17]; [@bib14]). Thus, DLK-dependent regeneration depends in part on *parg-1* and *parg-2.*

In addition to controlling axon regeneration, DLK signaling regulates presynaptic development ([@bib17]). To test whether presynaptic development is regulated by PARylation, we quantified synapses at the GABA neuromuscular junction with the pre-synaptic reporter *hpIs3*. The *hpIs3* reporter expresses GFP tagged SYD-2 (alpha-liprin) in presynaptic active zones of GABA motor neurons ([@bib38]). In control animals, SYD-2::GFP is distributed in a punctate pattern at regularly interspaced intervals along the dorsal nerve cord ([Figure 3](#fig3){ref-type="fig"}) ([@bib36]). Loss of all PARG activity did not affect synapse morphology. Increased DLK signaling in *dlk-1(OE)* animals causes synapse morphology defects ([Figure 3](#fig3){ref-type="fig"}) ([@bib17]). In *dlk-1(OE)* animals, SYD-2::GFP is diffuse along the dorsal nerve cord, which increases the average baseline fluorescence along a line scan ([Figure 3](#fig3){ref-type="fig"}). However, loss of PARG activity did not suppress these defects. Together, these data indicate that in contrast to its role in axon regeneration, PARylation does not regulate synapse formation, even when DLK signaling is activated.10.7554/eLife.12734.006Figure 3.Loss of *parg-1* and *parg-2* function does not suppress mislocalizion of presynaptic active zones caused by *dlk-1* overexpression.(**A**) Dorsal nerve cords of wild type, *dlk-1(OE), parg-1(lf) parg-2(lf)*, and *dlk-1(OE); parg-1(lf) parg-2(lf)* animals. All animals express the presynaptic active zone marker SYD-2::GFP in their GABA neurons. SYD-2::GFP is expressed in discrete puncta (arrowhead) in wild type animals and is not expressed continuously along the dorsal cord (asterisk). Conversely, SYD-2::GFP is expressed in a diffuse pattern (arrow) in *dlk-1(OE)* animals. (**B**) Average maxima and average baseline fluorescence are calculated along line scans of each dorsal cord and represented in (**C**). (**C**) *dlk-1* overexpression disrupts SYD-2::GFP expression in GABA neurons and results in higher baseline fluorescence compared to wild type. Loss of parg function does not affect localization of SYD-2::GFP nor does it suppress the mislocalization caused by *dlk-1(OE)* (\*p\<0.05, \*\*\*p\<0.01, multiple ANOVA, Bonferroni post-test). (**D**) There are no significant differences in average maxima between genotypes. Sample size is 15, 8, 8, and 15 animals for *wild type*, *dlk-1(OE), parg-1(lf) parg-2(lf)*, and *dlk-1(OE); parg-1(lf) parg-2(lf)* animals, respectively.**DOI:** [http://dx.doi.org/10.7554/eLife.12734.006](10.7554/eLife.12734.006)

Axon injury triggers an acute response that includes activation of DLK signaling ([@bib34]). PARylation is a short-lived modification, and PAR levels are normally maintained by the continuous activity of PARP and PARG proteins ([@bib23]; [@bib12]). These data suggest a model in which increased PARG expression downstream of DLK signaling acutely reduces PAR levels in response to axon injury, thereby facilitating regeneration. We hypothesized that acute reduction of PAR levels by inhibition of PARP might also increase axon regeneration after injury, potentially similar to increased regeneration in PARP mutants ([Figure 2](#fig2){ref-type="fig"}). Multiple chemical PARP inhibitors are currently in preclinical and clinical trials for indications including cancer therapy and stroke ([@bib8]; [@bib2]). We found that treatment with chemical PARP inhibitors after injury resulted in significantly enhanced axon regeneration in vivo in *C. elegans* GABA neurons and in vitro in murine cortical neurons ([Figure 4A--C](#fig4){ref-type="fig"}, and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Drug treatment post-injury also improved behavioral recovery, demonstrating that enhanced regeneration after PARP inhibition results in functional reconnection ([Figure 4D,E](#fig4){ref-type="fig"}). Thus, acute poly(ADP-ribose) levels determine the response of neurons to axon injury, and inhibition of PARP after injury is sufficient to improve regeneration.10.7554/eLife.12734.007Figure 4.Chemical PARP inhibition enhances axon regeneration post-injury.(**A**) Micrographs of regenerating axons placed on plates containing DMS0 or PARP inhibitor (A966492, Selleckchem, 100 µM) immediately after surgery. (**B**) Acute chemical inhibition of PARP function enhances regeneration (\*p\<0.05, Fisher's exact test, n = 34 and 19 axons severed in animals exposed to DMSO or PARP inhibitor, respectively). (**C**) Axon regeneration is increased in murine cortical neurons exposed to chemical PARP inhibitor A966492 (\*p=0.0149, Student's t-test, n = 10). (**D**) To assess functional regeneration, all GABA neurons were severed and animals were assessed for their ability to reverse in response to a touch on the nose from a platinum wire. (**E**) One hour after all GABA neurons are severed, animals are incapable of reversing in response to a touch on the nose (shrinker). As functional connections are regenerated, animals recovered on PARP inhibitor displayed more backward movement than those recovered on DMSO (measured as number of body bends). Significantly more animals on PARP inhibitors recovered wild type function (4+ body bends, \*p\<0.05, Fisher's exact test, n = 11 and 9 animals exposed to DMSO or PARP inhibitor, respectively). (**F**) The balance between PARP and PARG regulates axon regeneration and is altered by chemical PARP inhibitors.**DOI:** [http://dx.doi.org/10.7554/eLife.12734.007](10.7554/eLife.12734.007)10.7554/eLife.12734.008Figure 4---figure supplement 1.Chemical PARP inhibitors have different effects on axon regeneration.Axon regeneration frequencies of *wildtype* animals placed on DMSO, Olaparib, Velaparib, or PJ34, post-axotomy. Regeneration was scored as (**A**) proportion of cut axons that regenerated, (**B**) proportion of regenerating axons that fully regenerated to the dorsal nerve cord (see [Figure 2C](#fig2){ref-type="fig"}), and (**C**) proportion of severed neurons that extended a secondary process rather than regenerate the severed axon.\*p\<0.05, Fisher's exact test, relative to wild type; error bars represent 95% confidence intervals; n = 32, 22, 22, 26).**DOI:** [http://dx.doi.org/10.7554/eLife.12734.008](10.7554/eLife.12734.008)

Together, our findings suggest that regulation of PARylation is an important component of the DLK pathway role in the axon regeneration mechanism. Multiple lines of evidence suggest the *parg* genes are transcriptionally regulated downstream of DLK signaling to promote regeneration. First, we find both of the *parg* genes are upregulated in animals with activated DLK signaling. Second, we find that endogenous *dlk-1* signaling drives *parg-2* expression in an injury-dependent manner. Third, we find that loss of the *parg* genes reduces regeneration, both in animals with endogenous levels of *dlk-1* activity and in animals with elevated DLK-1 signaling. These findings suggest a linear model in which DLK signaling induces *parg* expression, which in turn facilitates regeneration by removing PAR.

In addition to regulating PARylation, our data indicate that DLK signaling regulates regeneration upstream of multiple effectors. Although PARylation has a strong effect on regeneration in both animals with wild-type levels of *dlk-1* and in animals that overexpress *dlk-1*, some GABA axons in *parg-1(lf) parg-2(lf)* mutants are still able to regenerate ([Figure 1F](#fig1){ref-type="fig"}), indicating high levels of PAR do not completely prevent DLK-mediated axon regeneration. By contrast, GABA axons do not regenerate in animals lacking DLK ([@bib14]; [@bib35]). These data suggest that DLK activity has other functions besides regulating PARylation. Some of these functions may be mediated by other transcriptional outputs of DLK signaling ([@bib32]). Understanding these factors, as well as understanding the cellular effects of PAR on regeneration, await further study.

Besides shedding light on functional outputs of DLK signaling, our findings identify a novel pathway, involving control of poly(ADP-ribose) levels, that regulates axon regeneration ([Figure 4F](#fig4){ref-type="fig"}). Specifically, we find that PARG and PARP activity regulate the acute response of neurons to axon injury, and that chemical PARP inhibition after injury is sufficient to improve regeneration. The lack of additive phenotype in the double loss of function *parg-1(-); parg-2(-)* mutant suggests the two *parg* genes are not partially redundant. Rather, *parg-1* and *parg-2* may function together, for example as part of a complex. In *Arabidopsis thaliana*, the two *PARG* homologs physically interact ([@bib26]), suggesting the *PARG* homologs may function coordinately. Alternatively, concerted action of both PARGs may be required to maintain PAR levels below a threshold. In this model, loss of either single PARG results in a sufficient PAR increase to block regeneration, but increasing PAR beyond this threshold does not further reduce regeneration.

Previous investigations of the relationship between the two *C. elegans parg* homologs have been complicated by the physical proximity of the two genes in the genome. As a result, double loss of function mutants have been generated using RNAi. Since RNAi can result in incomplete knockdown of target genes, it has been difficult to determine the functional redundancy of the two genes using this approach. The *parg-1; parg-2* mutant described here may be useful for further characterization of animals that completely lack PARG function.

In vivo, injured mammalian axons must overcome extrinsic growth inhibition to regenerate. PARP1 is upregulated in murine cortical neurons exposed to inhibitory growth molecules (myelin-associated glycoprotein, Nogo-A, Chondroitin sulfate proteoglycans) in vitro and in crushed optic nerves in vivo. Moreover, inhibiting PARP1 promotes neurite outgrowth on inhibitory substrates in vitro ([@bib5]). Since PARPs and PARGs have contrasting effects on PAR levels, NAD+ levels, which are substrates of PAR ([@bib3]), and on axon regeneration, we conclude the balance between PARP and PARG function regulates axon regeneration, and present the hypothesis the PARG-PARP balance may determine axon regeneration by regulating PAR levels or by regulating NAD+ levels. Finally, the conservation of the role of PARP in mammalian axon regeneration may have important implications for nerve repair following injury or disease.

Materials and methods {#s3}
=====================

*C. elegans* strains {#s3-1}
--------------------

Strains were maintained as previously described at 20°C ([@bib4]). Some strains were provided by the CGC, which is funded by NIH Office of Research Infrastructure Programs (P40 OD010440). Specific mutations analyzed: *parg-1(gk120), parg-2(ok980), parp-1(ok988), parp-2(ok344), wpIs9\[Punc-47:DLK-1mini-GFP, ccGFP\], pmk-3(ok169), hpIs3\[punc-25::SYD-2::GFP; lin-15+\]*. To visualize GABA neurons in regeneration assays, mutants were crossed into the *oxIs12 \[Punc-47:GFP, lin-15+\]* background. XE1347 *wpIs39\[Punc-47:mCherry\],* XE1551 *wpIs9\[Punc-47:DLK-1mini-GFP, ccGFP\]; wpIs39\[Punc-47:mCherry\], and* XE1552 *wpIs9\[Punc-47:DLK-1mini-GFP, ccGFP\]; pmk-3(ok169); wpIs39\[Punc-47:mCherry\]* were analysed by RNA Seq.

RNA-Seq {#s3-2}
-------

The SeqCel method was used to generate RNA Seq profiles of larval GABA neurons ([@bib27]). Briefly, L4 stage larvae were dissociated and *punc-47::mCherry*-labeled GABA neurons were isolated by FACS (BD FACSaria) from wild-type (XE1347), *dlk-1(OE)* (XE1551) and *dlk-1(OE); pmk-3(ok169)* (XE1552) strains; dead and damaged cells were excluded by DAPI staining. Experiments were performed in triplicate for each genotype. For RNA-Seq analysis, total RNA (5--10 ng) was amplified by SMARTer cDNA synthesis (Clonetech) and libraries sequenced (PE-100) using the HiSeq 2500 system (Illumina). RNA-Seq data were analyzed with CLC Genomics Workbench software (Qiagen). A global comparison (EDGE test) ([@bib22]) of wild-type vs *dlk-1(OE)* GABA neuron RNA-Seq data sets detected 386 transcripts that are significantly up-regulated ([\>]{.ul}2 fold, p\<0.05) in the *dlk-1(OE)* GABA neuron profile. A comprehensive analysis of these data sets will be presented elsewhere. The *parg-2* transcript was significantly enriched (187x, p=1.6 e^−14^) in the *dlk-1(OE)* profile. The *parg-1* transcript was 2.5 fold elevated in *dlk-1(OE)* but was excluded from this initial analysis due to a conservative p-value correction for multiple testing. We identified *parg-1* as a likely false negative in this global analysis due to statistically significant elevation of the *parg-1* signal in a direct comparison with wild-type and *pmk-3(ok169)* (XE1552) (see [Figure 1A](#fig1){ref-type="fig"}).

Expression analysis {#s3-3}
-------------------

*Pparg-2::NLS::mCherry::NLS* was constructed by combining Gateway plasmids encoding the *parg-2* promoter sequence (obtained from GE Dharmacon Promoterome collection), *NLS::mCherry::NLS* coding sequence, the *unc-54* UTR sequence, and *pCFJ150. Pparg-2::NLS::mCherry::NLS* was injected along with the *Pmyo-2::GFP* co-injection marker (expressed in the pharynx) into *wpIs9\[Punc-47:DLK-1mini-GFP, ccGFP\]; oxIs12\[Punc-47::GFP\]* animals. *wpIs9* was outcrossed from transgenic lines with wild type N2 males. mCherry expression was compared between animals carrying the same extra-chromosomal array in the presence or absence of *wpIs9*. The posterior 7 VD/DD GABA neurons in 10 worms were analyzed for each genotype. Expression was analysed with an Olympus DSU mounted on an Olympus BX61 microscope, Andor Neo sCMOS camera, and Lumen light source. Error bars represent 95% confidence intervals. Significance is indicated with an asterisk (p\<0.0001, Fisher exact test).

Axotomy experiments {#s3-4}
-------------------

Axotomy experiments were carried out as previously described ([@bib6]). Post-axotomy images were acquired with an Olympus DSU mounted on an Olympus BX61 microscope, Andor Neo sCMOS camera, and Lumen light source. Error bars represent 95% confidence intervals. Significance is indicated with an asterisk (p\<0.01, Fisher exact test).

CRISPR {#s3-5}
------

The double *parg-1(wp20) parg-2(ok980)* mutant was created by injecting sgRNA targeting *parg-1* sequence: aaagactacgaagactatgt and Cas9 into *parg-2(ok980)* animals. The resulting deletion of the 20th and 21st base pairs of the second *parg-1* exon is a frameshift mutation that creates a truncated protein.

Transgenics {#s3-6}
-----------

*Punc-47::parg-2* expressing animals were obtained by injecting *parg-2(ok980); oxIs12* worms with *pAB1019* DNA at 50 ng/μl along with *Punc-25::mCherry* at 10 ng/ul and *Pmyo-2:mCherry* at 2 ng/μl as a co-injection marker. 1 kb ladder was added at 50 ng/μl as carrier. The *pAB1019* plasmid was constructed by combining Gateway plasmids encoding the *unc-47* promoter sequence, *parg-2* coding sequence (obtained from GE Dharmacon ORFeome collection), the *unc-54 UTR* sequence, and *pCFJ150*.

Cortical axon regeneration assay {#s3-7}
--------------------------------

The mouse cortical neuron axon regeneration assay was performed by scrape injury of confluent cultures, as described previously ([@bib15]). Primary cortical cultures were established from E17 C57BL/6 mice. Digested cells were plated on 96-well poly-D-lysine coated plates at a density of 25,000 cells per well in 200 µL of plating medium. Lentiviral particles encoding control non-targeting or PARP1 shRNA clones (Sigma) were added on DIV3 (Day In Vitro 3) as described for other shRNAs ([@bib39]). On DIV8, 96-well cultures were scraped using a custom-fabricated 96-pin array and allowed to regenerate for another 72 hr before fixing with 4% paraformaldehyde. Regenerating axons in the scrape zone were visualized using an antibody against β3 tubulin (1:2000, mouse monoclonal; catalog \#G712A; Promega). Growth cones were visualized by staining for F-actin using rhodamine-conjugated phalloidin (1:2000, catalog \#R415, Life Technologies). Cell density was visualized using nuclear marker DAPI (0.1 μg/mL, catalog \#4083, Cell Signaling Technology). Images were taken on a 10X objective in an automated high-throughput imager (ImageXpress Micro XLS, Molecular Devices) under identical conditions. Regeneration zone identification, image thresholding and quantitation were performed using an automated MATLAB script in a fully automated fashion.

Synapse analysis {#s3-8}
----------------

The synapse marker *hpIs3\[punc-25::SYD-2::GFP; lin-15+\]* was crossed onto indicated combinations of *parg(lf)* and *dlk-1(OE)* backgrounds. The dorsal cords of the resulting animals were imaged with a 40X oil objective on an UltraVIEW Vox (PerkinElmer) spinning disc confocal microscope (Nikon Ti-E Eclipse inverted scope; Hamamatsu C9100-50 camera) with Volocity software (Improvision). Images were analyzed with ImageJ.

PARP inhibitors {#s3-9}
---------------

All PARP inhibitors were acquired from Selleckchem. To assess the effects of PARP inhibitors on regeneration, GABA axons in L4 animals were axotomized and the worms placed on NGM plates ([@bib4]) containing 100 µM of the respective PARP inhibitor. Control plates were made with the same amount of DMSO as the plates containing inhibitor. Axon regeneration was scored 24 hr post-axotomy. Functional recovery was assessed by counting the number of body bends an animal made after being tapped on the nose with a platinum wire. Zero body bends is referred to as 'shrinker'.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Inhibiting Poly(ADP-Ribosylation) Improves Axon Regeneration\" for consideration by *eLife*. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by Kang Shen as the Reviewing Editor and a Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Both reviewers found this paper interesting and worth publishing despite the recently published paper that is relevant to this manuscript. Both reviewers found similar strengths and weaknesses in this work.

Summary:

Byrne and colleagues present an interesting manuscript that demonstrates a role for poly-ADP-ribosylation in the regulation of axonal regeneration in *C. elegans*. They find that overexpressing DLK, which promotes regeneration, leads to the upregulation of PARGS (glycohydrolases that remove PAR \[poly(ADP-ribose)\]. They show that loss of PARGS inhibits regeneration. PAR is generated by PARP1-here it is shown that genetic or pharmacological loss of PARP1 enhances regeneration. This is an interesting and well-done study that makes a significant contribution to the field. However, there are a number of suggestions to improve the manuscript. For example, both reviewers found the mammalian part of the paper to be somewhat preliminary and suggested cutting it out. Both reviewers also found it necessary to include more careful interpretation and discussion of the PARG double mutant, especially in the DLK OE case. One reviewer would also like to see the figure modified to include the *parg1, 2* DKO on the same histogram as the *dlk oe, parg1,2* DKO.

Essential revisions:

1\) Very recently, Langley and colleagues published a PNAS paper (PMID 26598704) that reached very similar conclusions. They showed in mammalian neurons that inhibiting PARPs improves axon regeneration, and also that axon injury induces the formation of PAR. I think two near simultaneous papers will highlight this interesting new result, and I find value in publishing the worm results. However, the Discussion section should incorporate this new paper.

2\) While the results presented are compelling, there is some question about the physiological relevance of the induction of PARGS, as this was only demonstrated in the case of DLK overexpression. While the authors do show that PARGs are necessary for regeneration, they do not show that they are regulated by injury. The authors have created a very nice transcriptional reporter of PARGs that has single cell resolution. It would strengthen the paper to test whether injury activates PARG using this reporter. If PARGs are regulated by injury, this would imply that they are an active part of the injury signaling mechanism rather than merely permissive factors for regeneration.

3\) The *parg1/parg2* double mutant has the same phenotype as each single mutant. While this could make sense for two components of a single pathway, that is not expected for these enzymes. Some discussion of this unexpected result is warranted.

4\) There is a small figure showing some role for Parp1 in mammalian axon regeneration. This makes use of shRNA targeting *parp1*. Appropriate controls were not included. First, it should be demonstrated that the shRNA actually leads to loss of *parp1*. Second, an effort should be made to show the phenotype is not due to an off-target effect. This could be done with sh-resistent cDNA rescue. An alternative is to use two independent PARP1 inhibitors (I suggest two to get around off target drug effects). These drugs are very well validated, and would give the story a hint of translational potential. If these controls cannot be done, this small figure should be removed. The point that this pathway is conserved in mammals is well demonstrated in the Langley paper.

5\) The authors claim that the DLK overexpression phenotype is partially suppressed by loss of *parg1* and *parg2*. In [Figure 2H](#fig2){ref-type="fig"}, it would be nice to include the level of regeneration seen in the *parg1/2* double knockout, so that it is clear to the reader that DLK OE still leads to improved axon regeneration in the absence of *parg1/2*. Indeed, I am unconvinced that it is fair to call this suppression. Loss of *parg1/2* leads to less regeneration in both the wild type background and the DLK overexpression background. In fact, DLK overexpression leads to very robust increase in regeneration in the absence of *parg1/2* (from \~30% to \~70%). In the presence of parg, DLK overexpression leads to an increase in regeneration from \~70% to about \~90%. Obviously there is a ceiling effect so it is difficult to compare, but I don\'t think these results clearly show that PARG is acting downstream of DLK. These are also the results you would expect if PARG were acting in a parallel pathway. A more balanced discussion of the interpretation is warranted.

6\) It is less clear on the significance of this pathway in regulating axon regeneration given the partial phenotype of *parg1/parg2* double mutant, with or without *dlk-1 OE*. With a single mammalian neuron culture experiment with shRNA knockdown, it also remains open how much this pathway plays a role in the mammalian system. Any speculation on the link between a role in axon regeneration and well established roles of PARGs and PARPs?

7\) Related to \#1 above, may want to do the same level of analyses in [Figure 2H](#fig2){ref-type="fig"} as in [Figure 2B-C](#fig2){ref-type="fig"} to dig deeper into the phenotype since at the first glance the phenotype is not strong in [Figure 2H](#fig2){ref-type="fig"}. Also for [Figure 2H](#fig2){ref-type="fig"}, how does *dlk-1(OE);parg-1(-);parg-2(-)* compare to *dlk-1(OE);pmk-3(-)?*

8\) Any way to directly measure poly(ADP-ribose) (PAR) levels? The conclusion is on PAR levels but there is no direct evidence on this.

9\) How does axon injury regulate *dlk-1 -- parg* and possibly *dlk-1 -- parp*? E.g., Does injury upregulate *parg-2* reporter gene expression? Is *parp* downregulated in *dlk-1 OE*? Given the experiments in cortical neurons, is PARG a transcriptional target of DLK in mammalian neurons?

10\) Why pick this gene (*parg-2*)? Top hit by fold change? More detailed description of top hits from the screen? E.g., any DLK-dependent and PMK3-independent hits?

10.7554/eLife.12734.010

Author response

Essential revisions:

*1) Very recently, Langley and colleagues published a PNAS paper (PMID 26598704) that reached very similar conclusions. They showed in mammalian neurons that inhibiting PARPs improves axon regeneration, and also that axon injury induces the formation of PAR. I think two near simultaneous papers will highlight this interesting new result, and I find value in publishing the worm results. However, the Discussion section should incorporate this new paper.*

Brochier et al. found inhibiting PARP improves neurite outgrowth of murine primary cortical neurons on inhibitory substrates in vitro, PAR is upregulated in primary neuronal cultures exposed to inhibitory growth molecules in vitro, and PAR is upregulated in crushed optic nerves in vivo. We agree that these results support our finding that after axon injury, PAR regulates axon regeneration and have incorporated discussion of these results into the paper. The revised manuscript includes the following:

"in vivo, injured mammalian axons must overcome extrinsic growth inhibition to regenerate. PAR levels are upregulated in murine cortical neurons exposed to inhibitory growth molecules (myelin-associated glycoprotein, Nogo-A, Chondroitin sulfate proteoglycans) in vitro and in crushed optic nerves in vivo. \[...\] Finally, the conservation of the role of PARP in mammalian axon regeneration may have important implications for nerve repair following injury or disease."

*2) While the results presented are compelling, there is some question about the physiological relevance of the induction of PARGS, as this was only demonstrated in the case of DLK overexpression. While the authors do show that PARGs are necessary for regeneration, they do not show that they are regulated by injury. The authors have created a very nice transcriptional reporter of PARGs that has single cell resolution. It would strengthen the paper to test whether injury activates PARG using this reporter. If PARGs are regulated by injury, this would imply that they are an active part of the injury signaling mechanism rather than merely permissive factors for regeneration.*

Thank you for the suggestion. As suggested, we investigated PARG expression after injury using the PARG reporter. We found expression of the PARG reporter is increased in GABA neurons after injury and the increase is dependent on *dlk-1*. This experiment demonstrates PARG is an active part of the injury signaling mechanism. This experiment also identified an unexpected role for *dlk* in regulating PARG in uninjured neurons.

We have included this result as [Figure 1B, C](#fig1){ref-type="fig"}, and modified the text as follows:

"To further test whether DLK regulates *parg* expression in GABA neurons, we built a reporter construct that expresses nuclear-localized mCherry driven by the *parg-2* promoter. \[...\] Thus, *parg-2* expression is upregulated in injured neurons and their neighbors, and dependent on *dlk-1.*

*3) The parg1/parg2 double mutant has the same phenotype as each single mutant. While this could make sense for two components of a single pathway, that is not expected for these enzymes. Some discussion of this unexpected result is warranted.*

We agree and have included discussion of the result as follows:

" The lack of additive phenotype in the double loss of function (*parg-1(lf) parg-2(lf))* mutant suggests the two *parg* genes are not partially redundant. \[...\] The *parg-1(lf) parg-2(lf)* mutant described here may be useful for further characterization of animals that completely lack PARG function."

*4) There is a small figure showing some role for Parp1 in mammalian axon regeneration. This makes use of shRNA targeting parp1. Appropriate controls were not included. First, it should be demonstrated that the shRNA actually leads to loss of parp1.*

We agree and to address the question, we performed western blots on cortical neurons exposed to negative control shRNA or to two unique shRNAs that target PARP1. We found exposure to PARP1 shRNAs caused a loss of PARP1 in cortical neurons. We have included the results in [Figure 2H and I](#fig2){ref-type="fig"}.

We included the following description in the Results and Discussion of the revised manuscript:

"To confirm the shRNA clones targeted PARP1, we performed western blots on cortical neurons exposed to negative control shRNA or to two unique shRNAs that target PARP1. \[...\] PARP was significantly reduced in neurons exposed to either of the PARP1-targeting shRNAs compared to negative control shRNA ([Figure 2H, I](#fig2){ref-type="fig"}). PARP levels were normalized to actin levels in each sample of neurons.

Second, an effort should be made to show the phenotype is not due to an off-target effect. This could be done with sh-resistent cDNA rescue. An alternative is to use two independent PARP1 inhibitors (I suggest two to get around off target drug effects). These drugs are very well validated, and would give the story a hint of translational potential.

We agree that we should control for off-target effects. We have two lines of evidence that demonstrate the increased regeneration seen in mammalian neurons after PARP inhibition is not due to an off-target effect: 1) Regeneration of cortical neurons is significantly increased when PARP function is inhibited by either of two unique shRNAs, 2) Regeneration of cortical neurons is significantly increased when PARP function is inhibited chemically. Together, these experiments suggest PARP is the relevant target.

These experiments are represented in [Figures 2F, G](#fig2){ref-type="fig"}, [4C](#fig4){ref-type="fig"} and described in the Results and Discussion section of the revised manuscript. In addition, Brochier et al. independently found cortical axon outgrowth on restrictive substrates is increased when PARP is inhibited with another chemical PARP inhibitor (Brochier et al., 2015). This complementary finding is described in the last paragraph of the Results and Discussion section.

" We cultured primary cortical mouse neurons in 96-well plates (Huebner et al., 2011). \[...\] We found that axons exposed to PARP1 shRNA regenerated significantly better than axons exposed to control shRNA ([Figure 2F, G](#fig2){ref-type="fig"})."

"We found that treatment with chemical PARP inhibitors after injury resulted in significantly enhanced axon regeneration in vivo in *C. elegans* GABA neurons and in vitro in murine cortical neurons ([Figure 4A, B, C](#fig4){ref-type="fig"}, and Figure 4---figure supplement 2)."

*5) The authors claim that the DLK overexpression phenotype is partially suppressed by loss of parg1 and parg2. In [Figure 2H](#fig2){ref-type="fig"}, it would be nice to include the level of regeneration seen in the parg1/2 double knockout, so that it is clear to the reader that DLK OE still leads to improved axon regeneration in the absence of parg1/2.*

We included the *parg1/2* double knockout data in [Figure 2J](#fig2){ref-type="fig"} (previously [Figure 2H](#fig2){ref-type="fig"}) and address the question of whether PARG is downstream of DLK below. The revised manuscript includes all four genotypes in the figure (now [Figure 2J](#fig2){ref-type="fig"} and included below): wild type, *parg1/2*, DLK OE, and *parg1/2*; DLK OE.

*Indeed, I am unconvinced that it is fair to call this suppression. Loss of parg1/2 leads to less regeneration in both the wild type background and the DLK overexpression background. In fact, DLK overexpression leads to very robust increase in regeneration in the absence of parg1/2 (from \~30% to \~70%). In the presence of parg, DLK overexpression leads to an increase in regeneration from \~70% to about \~90%. Obviously there is a ceiling effect so it is difficult to compare, but I don\'t think these results clearly show that PARG is acting downstream of DLK. These are also the results you would expect if PARG were acting in a parallel pathway. A more balanced discussion of the interpretation is warranted.*

We have rewritten this section of the manuscript and removed the term 'suppression'. We agree, our finding that loss of *parg1/2* reduces regeneration in both the wild type and the DLK overexpression backgrounds does not on its own show that parg is downstream of DLK. However, this finding, together with our finding that DLK overexpression increases parg expression ([Figure 1A](#fig1){ref-type="fig"}), and our finding that parg expression is dependent on DLK ([Figure 1C](#fig1){ref-type="fig"}), strongly suggest the PARGs act downstream of *dlk-1*. However, we cannot rule out the possibility that these pathways also have parallel functions. The revised section of the manuscript now reads:

"We assessed regeneration in animals with activated DLK signaling (*dlk-1(OE)*), but lacking both *parg-1* and *parg-2.* \[...\] Thus, DLK-dependent regeneration depends in part on *parg-1* and *parg-2.*"

"Together, our findings suggest that regulation of PARylation is an important component of the DLK pathway role in the axon regeneration mechanism. \[...\] Some of these functions may be mediated by other transcriptional outputs of DLK signaling (Watkins et al., 2013). Understanding these factors, as well as understanding the cellular effects of PAR on regeneration, await further study."

*6) It is less clear on the significance of this pathway in regulating axon regeneration given the partial phenotype of parg1/parg2 double mutant, with or without dlk-1 OE.*

We agree that compared to the DLK pathway, the PARGs and PARPs have a smaller effect on regeneration. However, our work on the PARGs/PARP pathway identifies a novel mechanism, PARylation, that significantly regulates the ability of an injured axon to regenerate after injury. Further, this mechanism is distinct from DLK in that it is 1) druggable; 2) affects functional recovery after injury; and 3) does not affect synaptic morphology. Thus, the role of the PARGs and PARPs is different from DLK. In our opinion, our findings are significant because they identify PARylation as important to the cell biology of axon regeneration, they reveal an axon regeneration-specific mechanism downstream of DLK, and they show that drugs that target this pathway improve axon regeneration and functional recovery.

*With a single mammalian neuron culture experiment with shRNA knockdown, it also remains open how much this pathway plays a role in the mammalian system.*

Please see our first two responses to \#4 above.

*Any speculation on the link between a role in axon regeneration and well established roles of PARGs and PARPs?*

Please see our response to \#8 below.

*7) Related to \#1 above, may want to do the same level of analyses in [Figure 2H](#fig2){ref-type="fig"} as in [Figure 2B-C](#fig2){ref-type="fig"} to dig deeper into the phenotype since at the first glance the phenotype is not strong in [Figure 2H](#fig2){ref-type="fig"}.*

[Figure 2H](#fig2){ref-type="fig"} is now [Figure 2J](#fig2){ref-type="fig"}. We reanalyzed the data and determined whether each axon regenerated below the midline of the worm (M-), beyond the midline (M+), at least ¾ of the distance to the dorsal cord (M++). The analysis confirmed our initial finding that the greatest difference in regenerative ability between the genotypes is in overall regeneration, in other words, axons that showed some degree of regeneration (all blue bars in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). This analysis also indicates other, more granular phenotypes that may be of interest. We added the figure to the supplemental figures (Now [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

*Also for [Figure 2H](#fig2){ref-type="fig"}, how does dlk-1(OE);parg-1(-);parg-2(-) compare to dlk-1(OE);pmk-3(-)?*

As published in Hammarlund et al., 2009, 7% of *dlk-1OE; pmk-3(-)* axons regenerate. Thus, the suppression of *dlk-1OE* by *parg-1* and *parg-2* is not as strong, suggesting regulation of the *parg* genes is not the only mechanism that mediates regeneration downstream of the canonical *dlk-1* pathway. We have modified the text as follows (Results and Discussion section):

"We assessed regeneration in animals with activated DLK signaling (*dlk-1(OE)*), but lacking both *parg-1* and *parg-2.* \[...\] Thus, DLK-dependent regeneration depends in part on *parg-1* and *parg-2.*"

*8) Any way to directly measure poly(ADP-ribose) (PAR) levels? The conclusion is on PAR levels but there is no direct evidence on this.*

Unfortunately, although PAR levels can be measured in bulk preps, we do not have a way to detect the relevant PAR levels, specifically within the GABA neurons. Our data suggests PAR levels regulate axon regeneration since PARPs and PARGs have contrasting effects on PAR levels (Bai, 2015) and on axon regeneration. In addition, Brochier et al. found PAR levels are increased in injured axons in the optic nerve (Brochier et al., 2015). We modified the text as follows:

"Since PARPs and PARGs have contrasting effects on PAR levels, NAD+ levels (Bai, 2015) and on axon regeneration, we conclude the balance between PARP and PARG function regulates axon regeneration, and present the hypothesis the PARG-PARP balance may determine axon regeneration by regulating PAR levels or by regulating NAD+ levels."

*9) How does axon injury regulate dlk-1 -- parg and possibly dlk-1 -- parp? E.g., Does injury upregulate parg-2 reporter gene expression? Is parp downregulated in dlk-1 OE? Given the experiments in cortical neurons, is PARG a transcriptional target of DLK in mammalian neurons?*

As discussed in response to comment \#2 above, expression of the glycohydrolase (*parg-2*) reporter gene is upregulated by injury, and expression in both injured and uninjured neurons is *dlk-1*-dependent. By contrast, expression of the polymerases (*parp-1* or *parp-2*) is not significantly changed in *dlk-1OE* axons relative to wild type axons. PARG was not identified as one of 342 genes upregulated in a DLK-dependent manner in crushed optic nerves (Watkins et al., 2013). However, the Watkins investigation was performed three days after injury and does not preclude an earlier DLK-dependent response to injury.

*10) Why pick this gene (parg-2)? Top hit by fold change? More detailed description of top hits from the screen? E.g., any DLK-dependent and PMK3-independent hits?*

*parg-2* was the fourth-most upregulated gene in the *dlk-1OE* background whose upregulation was dependent on the downstream kinase *pmk-3*. Similarly, *parg-1* was also upregulated in the *dlk-1OE* background ([Figure 1A](#fig1){ref-type="fig"}). The presence of both paralogs made this gene family a particularly intriguing candidate. We did not include a description of any other candidate genes in this manuscript since including them would require a significant amount of validation, which we believe is beyond the scope of this paper. We have rewritten this section of the manuscript to describe how the *parg* genes were selected for analysis. The revised section now reads:

"RNA sequencing and analysis suggested the *parg* genes as candidates for further evaluation. \[...\] These data suggested that regulation of PARG function might be a major effect of DLK signaling."

[^1]: Department of Neurobiology, University of Massachusetts Medical School, Worcester, United States.
